Titan Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 4/6

Titan Pharmaceuticals possède un total de capitaux propres de $4.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $4.4M et de $356.0K.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$4.09m
Fonds propres	US$3.99m
Total du passif	US$356.00k
Total des actifs	US$4.35m

Mises à jour récentes de la santé financière

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Jul 10

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de TTNP ( $4.4M ) dépassent ses passifs à court terme ( $356.0K ).

Passif à long terme: TTNP n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: TTNP est sans dette.

Réduire la dette: TTNP n'a actuellement aucune dette, mais nous ne pouvons pas comparer avec il y a 5 ans car nous n'avons pas de données pour cette période.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: TTNP dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: TTNP dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 12.3 % chaque année.

Titan Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Recent updates

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the Board

Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction.

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines